Literature DB >> 7902175

Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung.

C J Whelan1, M Johnson, C J Vardey.   

Abstract

1. We have compared some anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung. 2. Intradermal formoterol (1 x 10(-10) to 1 x 10(-8) mol/site), salbutamol (1 x 10(-8) and 1 x 10(-7) mol/site) and salmeterol (1 x 10(-8) and 1 x 10(-7) mol/site) inhibited bradykinin-induced plasma protein extravasation (PPE) in guinea-pig skin. A maximally effective dose of formoterol (1 x 10(-9) mol/site) and salbutamol (1 x 10(-8) mol/site) inhibited PPE in guinea-pig skin for 2-4 h and 1-2 h respectively, whereas salmeterol (1 x 10(-8) mol/site) was effective for > 6 h. 3. Inhaled formoterol (nebuliser concentration 0.1 to 100 micrograms ml-1 inhibited histamine-induced plasma protein extravasation (PPE) in guinea-pig lung, with significant inhibition being observed at 10 and 100 micrograms ml-1. Formoterol (100 micrograms ml-1) inhibited PPE in guinea-pig lung for 2-4 h, a duration of action intermediate between that previously obtained for salbutamol (1 h) and salmeterol (> 6 h). 4. Formoterol, like salbutamol, had no effect on neutrophil accumulation or granulocyte-dependent PPE (zymosan-induced) in guinea-pig skin. Formoterol inhibited neutrophil accumulation (lipopolysaccharide-induced) in guinea-pig lung but at doses greater than those required to inhibit granulocyte-independent PPE (histamine-induced). In contrast, salmeterol inhibited neutrophil accumulation and granulocyte-dependent PPE in guinea-pig skin and inhibited neutrophil accumulation in guinea-pig lung at doses which inhibit granulocyte-independent PPE. 5. Inhaled formoterol (nebuliser concentration 100 microg ml-1) and salmeterol (100 microg ml-1) both inhibited PAF-induced eosinophil accumulation in guinea-pig lung. However, unlike salmeterol, this effect of formoterol was observed only at suprabronchodilator doses.6. We conclude that to inhibit neutrophil accumulation, at doses which inhibit granulocyte-independent PPE, agonists acting at beta-adrenoceptors on vascular endothelium require a duration of action greater than that of salbutamol and formoterol. However, we speculate that the mechanism of inhibition of eosinophil accumulation in guinea-pig lung by beta2-adrenoceptor agonists may involve an action on beta2-adrenoceptors on a cell type other than the endothelial cell.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7902175      PMCID: PMC2175955          DOI: 10.1111/j.1476-5381.1993.tb13855.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

1.  Evidence that the efficacy (intrinsic activity) of fenoterol is higher than that of salbutamol on beta-adrenoceptors in guinea-pig trachea.

Authors:  S R O'Donnell; J C Wanstall
Journal:  Eur J Pharmacol       Date:  1978-02-01       Impact factor: 4.432

2.  Inhibition of anti-IgE induced skin response in normals by formoterol, a new beta 2-adrenoceptor agonist, and terbutaline. 2. Effect on the late phase reaction.

Authors:  R Grönneberg; O Zetterström
Journal:  Allergy       Date:  1990-07       Impact factor: 13.146

3.  Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine.

Authors:  D W Cockcroft; K Y Murdock
Journal:  J Allergy Clin Immunol       Date:  1987-05       Impact factor: 10.793

4.  Formation of oedema and accumulation of eosinophils in the guinea pig lung. Inhibition by inhaled beta-stimulants.

Authors:  A Fügner
Journal:  Int Arch Allergy Appl Immunol       Date:  1989

5.  Modulation of arterial endothelial permeability: studies on an in vitro model.

Authors:  J R Gudgeon; W Martin
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

6.  Isoproterenol inhibition of isolated human neutrophil function.

Authors:  W W Busse; J M Sosman
Journal:  J Allergy Clin Immunol       Date:  1984-03       Impact factor: 10.793

Review 7.  The pharmacology of salmeterol.

Authors:  M Johnson; P R Butchers; R A Coleman; A T Nials; P Strong; M J Sumner; C J Vardey; C J Whelan
Journal:  Life Sci       Date:  1993       Impact factor: 5.037

8.  Inhibition of anti-IgE induced skin response in normals by formoterol, a new beta 2-adrenoceptor agonist, and terbutaline. 1. Dose response relation and duration of effect on the early wheal and flare response.

Authors:  R Grönneberg; O Zetterström
Journal:  Allergy       Date:  1990-07       Impact factor: 13.146

9.  Protection against allergen-induced asthma by salmeterol.

Authors:  O P Twentyman; J P Finnerty; A Harris; J Palmer; S T Holgate
Journal:  Lancet       Date:  1990-12-01       Impact factor: 79.321

10.  Recombinant human interleukin 5 is a selective activator of human eosinophil function.

Authors:  A F Lopez; C J Sanderson; J R Gamble; H D Campbell; I G Young; M A Vadas
Journal:  J Exp Med       Date:  1988-01-01       Impact factor: 14.307

View more
  10 in total

Review 1.  Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma.

Authors:  J C Adkins; D McTavish
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

2.  Anti-inflammatory effects of β2 adrenergic receptor agonists in experimental acute lung injury.

Authors:  Markus Bosmann; Jamison J Grailer; Ketong Zhu; Michael A Matthay; J Vidya Sarma; Firas S Zetoune; Peter A Ward
Journal:  FASEB J       Date:  2012-02-07       Impact factor: 5.191

3.  Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro.

Authors:  R Anderson; C Feldman; A J Theron; G Ramafi; P J Cole; R Wilson
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

4.  Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts.

Authors:  F M Spoelstra; D S Postma; H Hovenga; J A Noordhoek; H F Kauffman
Journal:  Thorax       Date:  2002-03       Impact factor: 9.139

Review 5.  Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease.

Authors:  Caroline Fenton; Gillian M Keating
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease.

Authors:  Erik P Riesenfeld; Michael J Sullivan; John A Thompson-Figueroa; Hans C Haverkamp; Lennart K Lundblad; Jason H T Bates; Charles G Irvin
Journal:  Respir Res       Date:  2010-02-24

7.  Inhibition of some aspects of acute inflammation of guinea-pig lung by intraperitoneal dexamethasone and mifepristone: demonstration of agonist activity of mifepristone in the guinea-pig.

Authors:  C J Whelan; S C Hughes; G P Wren
Journal:  Inflamm Res       Date:  1995-03       Impact factor: 4.575

8.  Comparing clinical efficacy of Symbicort versus Pulmicort in reducing asthma symptom and improving its control.

Authors:  Mohammad Emami; Azadeh Tayebi; Mojgan Gharipour; Somayeh Farzamnia; Akbar Kargari Temyarti
Journal:  Adv Biomed Res       Date:  2014-02-28

9.  Effects of β2-adrenergic agonists on house dust mite-induced adhesion, superoxide anion generation, and degranulation of human eosinophils.

Authors:  Yutaka Ueda; Kazuyuki Nakagome; Takehito Kobayashi; Toru Noguchi; Tomoyuki Soma; Katsuyo Ohashi-Doi; Kenichi Tokuyama; Makoto Nagata
Journal:  Asia Pac Allergy       Date:  2020-04-22

Review 10.  COPD exacerbations: defining their cause and prevention.

Authors:  Jadwiga A Wedzicha; Terence A R Seemungal
Journal:  Lancet       Date:  2007-09-01       Impact factor: 79.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.